Síndrome de lipodistrofia associada ao HIV: prevalência, impacto metabólico e qualidade de vida
DOI:
https://doi.org/10.34119/bjhrv8n5-005Keywords:
HIV, lipodistrofia, síndrome metabólica, qualidade de vida, antirretroviraisAbstract
Objetivo: Realizar uma revisão narrativa sobre a síndrome de lipodistrofia associada ao HIV, com foco em sua prevalência, implicações metabólicas e impacto na qualidade de vida. Métodos: Foi conduzida uma busca na base PubMed utilizando os descritores “HIV Infections AND Lipodystrophy AND Metabolic Syndrome AND Quality of Life”, abrangendo estudos publicados entre 1999 e 2025. Foram selecionados 21 artigos que abordavam diretamente o tema. Resultados: Os estudos incluídos evidenciaram que a lipodistrofia é uma condição frequente entre pacientes vivendo com HIV, especialmente em esquemas prolongados de TARV. Está associada a dislipidemia, resistência à insulina e aumento do risco cardiovascular, além de repercussões psicossociais importantes, como estigma, baixa autoestima e prejuízo na adesão ao tratamento. Conclusão: A lipodistrofia representa uma complicação relevante e multifatorial da TARV. Seu manejo exige abordagem clínica individualizada, integração de múltiplas especialidades e atenção aos aspectos físicos, metabólicos e emocionais.
References
MARTÍNEZ, E.; GARCIA‑VIEJO, M. A.; BLANCH, L.; GATELL, J. M. Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf., 2001, v. 24, n. 3, p. 157–166. DOI: 10.2165/00002018‑200124030‑00001.
FINKELSTEIN, J. L.; GALA, P.; ROCHFORD, R.; GLESBY, M. J.; MEHTA, S. HIV/AIDS and lipodystrophy: implications for clinical management in resource‑limited settings. J Int AIDS Soc., 2015, v. 18, n. 1, p. 19033. DOI: 10.7448/IAS.18.1.19033.
KINO, T.; MIRANI, M.; ALESCI, S.; CHROUSOS, G. P. AIDS‑related lipodystrophy/insulin resistance syndrome. Horm Metab Res., 2003, v. 35, n. 3, p. 129–136. DOI: 10.1055/s‑2003‑39072.
POTTHOFF, A.; BROCKMEYER, N. H.; GELBRICH, G.; et al. Lipodystrophy – a sign for metabolic syndrome in patients of the HIV‑HEART study. J Dtsch Dermatol Ges., 2010, v. 8, n. 2, p. 92–98. DOI: 10.1111/j.1610‑0387.2009.07330.x.
GUZMÁN‑VELASCO, S.; PON, F.; OLONA, M.; et al. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV‑infected patients. Curr Pharm Des., 2010, v. 16, n. 30, p. 3379–3389. DOI: 10.2174/138161210793563518.
NETO, M. G.; CONCEIÇÃO, C. S.; OGALHA, C.; BRITES, C. Aerobic capacity and health‑related quality of life in adults HIV‑infected patients with and without lipodystrophy. Braz J Infect Dis., 2016, v. 20, n. 1, p. 76–80. DOI: 10.1016/j.bjid.2015.11.001.
FALUTZ, J. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications. Best Pract Res Clin Endocrinol Metab., 2011, v. 25, n. 3, p. 517–529. DOI: 10.1016/j.beem.2010.11.001.
BARBARO, G.; BARBARINI, G. Highly active antiretroviral therapy‑associated metabolic syndrome and cardiovascular risk. Chemotherapy, 2006, v. 52, n. 4, p. 161–165. DOI: 10.1159/000093034.
GARCÍA‑VIEJO, M. A.; RUÍZ, M.; MARTÍNEZ, E. Strategies for treating HIV‑related lipodystrophy. Expert Opin Investig Drugs, 2001, v. 10, n. 8, p. 1443–1456. DOI: 10.1517/13543784.10.8.1443.
GUARALDI, G.; MURRI, R.; ORLANDO, G.; et al. Severity of lipodystrophy is associated with decreased health‑related quality of life. AIDS Patient Care STDS, 2008, v. 22, n. 7, p. 577–585. DOI: 10.1089/apc.2007.0173.
TILHET, L.; ROUANET, M.; HENRY, A.‑S.; et al. Current status and perspectives in the treatment of facial lipoatrophy in HIV‑positive patients in 2024. Ann Chir Plast Esthet., 2025, v. 70, n. 3, p. 192–205. DOI: 10.1016/j.anplas.2024.10.006.
COLLINS, E.; WAGNER, C.; WALMSLEY, S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read, 2000, v. 10, n. 9, p. 546–550.
RAJAGOPALAN, R.; LAITINEN, D.; DIETZ, B. Impact of lipoatrophy on quality of life in HIV patients receiving anti‑retroviral therapy. AIDS Care, 2008, v. 20, n. 10, p. 1197–1201. DOI: 10.1080/09540120801926993.
FALUTZ, J. Therapy insight: Body‑shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Nat Clin Pract Endocrinol Metab., 2007, v. 3, n. 9, p. 651–661. DOI: 10.1038/ncpendmet0587.
BARRAGÁN, P.; FISAC, C.; PODZAMCZER, D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev, 2006, v. 8, n. 4, p. 191–203.
PÉREZ‑MATUTE, P.; PÉREZ‑MARTÍNEZ, L.; BLANCO, J. R.; et al. Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV‑positive patients but not to diagnose HIV‑associated lipoatrophy: a pilot study. J Int AIDS Soc., 2013, v. 16, p. 18609. DOI: 10.7448/IAS.16.1.18609.
LO, J.; YOU, S. M.; CANAVAN, B.; et al. Low‑dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA, 2008, v. 300, n. 5, p. 509–519. DOI: 10.1001/jama.300.5.509.
FALUTZ, J.; ALLAS, S.; KOTLER, D.; et al. A placebo‑controlled, dose‑ranging study of a growth hormone releasing factor in HIV‑infected patients with abdominal fat accumulation. AIDS, 2005, v. 19, n. 12, p. 1279–1287. DOI: 10.1097/01.aids.0000180099.35146.30.
LAKE, J. E.; MCCOMSEY, G. A.; HULGAN, T. M.; et al. A randomized trial of Raltegravir replacement for protease inhibitor or non‑nucleoside reverse transcriptase inhibitor in HIV‑infected women with lipohypertrophy. AIDS Patient Care STDS, 2012, v. 26, n. 9, p. 532–540. DOI: 10.1089/apc.2012.0135.
DE SANTIS, G.; PIGNATTI, M.; BACCARANI, A.; et al. Long‑term efficacy and safety of polyacrylamide hydrogel injection in the treatment of human immunodeficiency virus‑related facial lipoatrophy: a 5‑year follow‑up. Plast Reconstr Surg., 2012, v. 129, n. 1, p. 101–109. DOI: 10.1097/PRS.0b013e3182362142.
MAYANJA, B. N.; KASAMBA, I.; LEVIN, J.; et al. COHORT PROFILE: The Complications of Long‑Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther, 2017, v. 14, art. 26. DOI: 10.1186/s12981‑017‑0154‑y.
